Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2017
Price : $35 *
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TIG3
- Sponsors Janssen-Cilag
- 11 Feb 2016 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
- 19 May 2015 Accrual to Date is 100% according to United kingdom Clinical Research Network
- 27 Mar 2015 New source identified and integrated (European Clinical Trials Database Record:EudraCT2013-003729-27).